Skip to main content
Diagnostics logoLink to Diagnostics
. 2021 Nov 14;11(11):2106. doi: 10.3390/diagnostics11112106

Breast Carcinomatous Lymphangitis as an Unusual Presentation of Ovarian Cancer

Barbara Muoio 1, Giorgio Treglia 2,3,4,*, Paola Migliora 5, Maria Del Grande 1
Editor: Andreas Kjaer
PMCID: PMC8623972  PMID: 34829453

Abstract

We describe the case of a 45-year-old woman with an unusual presentation of metastatic ovarian cancer. The patient presented to the oncological clinic with a three-week history of skin rash on the right breast. She underwent a chest and abdomen CT scan, which showed skin thickening of the right breast, right pleural effusion and bilateral cystic ovarian masses. Biopsy of a left ovarian lesion by diagnostic laparoscopy revealed the presence of ovarian serous carcinoma. Biopsy of the breast skin lesion revealed the presence of carcinomatous lymphangitis and immunohistochemistry documented the ovarian origin.

Keywords: carcinomatous lymphangitis, breast, ovarian cancer, imaging, pathology


Figure 1.

Figure 1

A 45-year-old woman presented to the oncological clinic with a three-week history of skin rash on the right breast ((A); arrow). The patient underwent a chest and abdomen CT scan (B,C), which showed skin thickening of the right breast ((B); upper arrow), right pleural effusion ((B); lower arrow) and bilateral cystic ovarian masses ((C); arrow). Biopsy of a left ovarian lesion by diagnostic laparoscopy revealed the presence of ovarian serous carcinoma. The patient performed other staging exams (breast ultrasound and mammography) which were suspicious for carcinomatous lymphangitis. Biopsy of the breast skin lesion revealed the presence of carcinomatous lymphangitis (D), whereas immunohistochemistry showed negativity for CK20, GATA3 (E) and positivity for CK7 (F), PAX8 and WT1. The immunochemistry pattern demonstrated the ovarian origin of breast lesions. After the diagnosis of metastatic disease, the patient underwent chemotherapy with carboplatin and paclitaxel with partial radiological response after three cycles. Due to inoperable disease, the patient continued chemotherapy with the addition of bevacizumab, obtaining partial treatment response at last follow-up (about one year after the diagnosis of carcinomatous lymphangitis). Carcinomatous lymphangitis may be a metastatic manifestation of different tumors; the most common primary sites are breast, lung and stomach, whereas in rare cases it can be due to ovarian cancer [1,2,3,4,5,6,7,8]. In the described case, an integrated diagnostic approach was very useful to detect breast carcinomatous lymphangitis as an uncommon presentation of metastatic ovarian cancer.

Author Contributions

Conceptualization, B.M. and M.D.G.; investigation, B.M., P.M. and M.D.G.; data curation, B.M., P.M. and M.D.G.; writing—original draft preparation, B.M. and G.T.; writing—review and editing, M.D.G. and G.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Written informed consent was obtained from the patient to publish this paper.

Data Availability Statement

Original data supporting the reported results are available contacting the authors.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Cruz R.P., Rodini G.P., da Rosa M.D., Cabral V.D., Cambruzzi E., Ferrandina G., Ribeiro R. Intestinal lymphangitis carcinomatosa related to ovarian cancer: Case report and review of the literature. Gynecol. Oncol. Rep. 2020;33:100606. doi: 10.1016/j.gore.2020.100606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Martynychen M.G., Rabelo L.M., Silva R.L., Escuissato D.L. Carcinomatous lymphangitis as the initial manifestation of ovarian adenocarcinoma. J. Bras. Pneumol. 2007;33:609–611. doi: 10.1590/S1806-37132007000500018. [DOI] [PubMed] [Google Scholar]
  • 3.Hominal S., Falchero L., Perol M., Guérin J.C. Lymphangite carcinomateuse [Carcinomatous lymphangitis] Presse Med. 1999;28:979–984. [PubMed] [Google Scholar]
  • 4.Burns Z., Omar L., Compton L., Hayes J., Sahoo S., Merchant K. Lymphangitic spread of invasive lobular carcinoma to the contralateral breast. Clin. Imaging. 2019;58:187–190. doi: 10.1016/j.clinimag.2019.08.002. [DOI] [PubMed] [Google Scholar]
  • 5.Burbano J., Salazar-González A., Echeverri C., Rendón G., Gaviria M., Pareja R. Cutaneous lymphangitic carcinomatosis: A rare metastasis from cervical cancer. Gynecol. Oncol. Rep. 2018;26:1–3. doi: 10.1016/j.gore.2018.07.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lebeck Lee C., Zwerner J., O’Brian B., Eng C. Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. Clin. Colorectal. Cancer. 2021 doi: 10.1016/j.clcc.2021.09.010. [DOI] [PubMed] [Google Scholar]
  • 7.Biswas A., Sriram P.S. Getting the whole picture: Lymphangitic carcinomatosis. Am. J. Med. 2015;128:837–840. doi: 10.1016/j.amjmed.2015.04.007. [DOI] [PubMed] [Google Scholar]
  • 8.Massollo M., Fiz F., Bottoni G., Ugolini M., Paparo F., Puppo C., Provinciali N., Iacozzi M., Altrinetti V., Cistaro A., et al. To Enhance or Not to Enhance? The Role of Contrast Medium 18F-FDG PET/CT in Recurrent Ovarian Carcinomas. Medicina. 2021;57:561. doi: 10.3390/medicina57060561. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Original data supporting the reported results are available contacting the authors.


Articles from Diagnostics are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES